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Abstract
AIMS: The aim of this study was to assess the prevalence of abnormal liver
function tests (LFTs) and the associated clinical profile and outcome(s) in
acute decompensated heart failure (ADHF) patients. Alteration in LFTs is a
recognized feature of ADHF, but prevalence and outcomes data from a broad
contemporary cohort of ADHF are scarce and the mechanism(s) of ADHF-
induced cholestasis is unknown. METHODS AND RESULTS: We conducted a
post hoc analysis of SURVIVE, a large clinical trial including ADHF patients
treated with levosimendan or dobutamine. All LFTs were available in 1134
patients at baseline. Abnormal LFTs were seen in 46% of ADHF patients: isolated
abnormal alkaline phosphatase (AP) was noted in 11%, isolated abnormal
transaminases in 26%, and a combination of abnormal AP and transaminases
in 9%. Abnormal AP was associated with marked signs of systemic congestion
and elevated right-sided filling pressure. Abnormal AP had no relationship with
31-day mortality but was associat...
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Aims The aim of this study was to assess the prevalence of abnormal liver function tests (LFTs) and the associated clinical
profile and outcome(s) in acute decompensated heart failure (ADHF) patients. Alteration in LFTs is a recognized
feature of ADHF, but prevalence and outcomes data from a broad contemporary cohort of ADHF are scarce and
the mechanism(s) of ADHF-induced cholestasis is unknown.
Methods
and results
We conducted a post hoc analysis of SURVIVE, a large clinical trial including ADHF patients treated with levosimendan
or dobutamine. All LFTs were available in 1134 patients at baseline. Abnormal LFTs were seen in 46% of ADHF
patients: isolated abnormal alkaline phosphatase (AP) was noted in 11%, isolated abnormal transaminases in 26%,
and a combination of abnormal AP and transaminases in 9%. Abnormal AP was associated with marked signs of sys-
temic congestion and elevated right-sided filling pressure. Abnormal AP had no relationship with 31-day mortality but
was associated with worse 180-day mortality (23.5 vs. 34.9%, P ¼ 0.001 vs. patients with normal AP). Abnormal
transaminases were associated with clinical signs of hypoperfusion and with greater 31-day and 180-day mortality
compared with normal transaminase profiles (17.6 vs. 8.4% and 31.6 vs. 22.4%, respectively; both P, 0.001).
There was no additive value of abnormal AP plus abnormal transaminase on a long-term outcome.
Conclusion Abnormal LFTs were present in about a half of patients presenting with ADHF treated with inotropes. Abnormal AP
and abnormal transaminases were associated with specific clinical, biological, and prognostic features, including a
short-term overmortality with increased transaminases but not with biological signs of cholestasis, in ADHF patients.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Heart failure † Liver † Prognosis † Inotropic agents
Introduction
Heart failure (HF) is a clinical syndrome associated with
haemodynamic changes that may result in pressure-related
damage to one or more organs.1,2 Interactions between renal
and cardiac dysfunction have been recently construed to be
‘cardiorenal syndromes’, including subtypes with specific patho-
physiology, diagnostic and prognostic values, and management
strategies.3 – 5
Liver involvement has been mostly described and investigated in
patients with chronic HF.6,7 Liver enzyme alterations are usually
classified as relating predominantly to liver cell necrosis (signified
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by transaminase elevations) or predominantly to cholestasis [signi-
fied by elevated alkaline phosphatase (AP) levels].8,9
The prognostic importance of abnormalities in liver function
tests (LFTs) has varied among published studies. The unfavourable
predictive value of abnormal LFTs has been described in patients
with chronic HF10 or acute decompensated heart failure
(ADHF).11 Total bilirubin was among the most highly significant
predictors of mortality in a post hoc analysis of a large cohort of
chronic HF patients in a clinical trial.12 However, a
haemodynamic-independent prognostic value of liver function ab-
normalities was not found in a recent analysis of 323 patients
with a history of HF.13
In the acute-care setting, hepatocyte necrosis has been the most
frequently described histological finding associated with alteration
in LFTs, in the cases of severe circulatory shock,14 or severe
ADHF.15 However, the prevalence of altered LFTs (signifying hepa-
tocellular lysis and/or cholestasis) in a large contemporary cohort
of ADHF patients is unknown.
The purpose of this study was to prospectively characterize
LFTs in a large, representative, well-treated cohort of ADHF
patients. SURVIVE was a large clinical trial involving patients with
ADHF in whom LFTs were performed before and after inotrope
infusion.16 The aims of this post hoc analysis of the SURVIVE trial
were to assess: (i) the prevalence and the clinical profile of patients
admitted for ADHF and abnormal LFTs; and (ii) the impact of
abnormal LFTs on short- and long-term outcomes.
Methods
Study population
SURVIVE was a randomized, double-blind, international, multi-centre,
parallel-group study of levosimendan vs. dobutamine in patients with
severe ADHF. Participating patients had the left ventricular ejection
fraction (LVEF) ,30% and were hospitalized for ADHF requiring ino-
tropic support.16,17 In accordance with non-inclusion criteria, all en-
rolled patients had systolic blood pressure (SBP) .85 mm Hg;
hence, cardiogenic shock patients were not enrolled. A great majority
of patients (88%) had a known history of HF. Patients with severe
hepatic failure (definition of which was at the discretion of the treating
physicians) were not included from the main study because levosimen-
dan is metabolized in the liver. In addition, patients with abnormal LFTs
attributed to chronic hepatic inflammatory disease, substance abuse,
or hepatotoxic medication were also not included in the SURVIVE
trial. The main result of SURVIVE was that all-cause mortality at 180
days occurred in 26% patients in the levosimendan group and 28%
patients in the dobutamine group (hazard ratio, 0.91; 95% confidence
interval, 0.74–1.13; P ¼ 0.40) and that the levosimendan group had
greater decreases in the B-type natriuretic peptide level at 24 h that
persisted through 5 days compared with the dobutamine group.16
The population of the present substudy comprised patients included
in the SURVIVE study who had all LFTs available at baseline (n ¼
1134) without taking into account any extra inclusion or exclusion cri-
teria. Liver function tests were also performed at Days 1, 3, 5, and 31.
Biochemical measurements
Liver function tests were measured in a core laboratory (Roche,
Modular-P chemical analyser, Icon clinical research, Ireland) and con-
sidered abnormal when levels exceeded 47 U/L for alanine
transaminase (ALT), 37 U/L for aspartate transaminase (AST), and
135 U/L for AP. B-type natriuretic peptide (BNP) and creatinine
levels were also recorded.
Statistical analyses
Baseline demographic and clinical characteristics are presented as
means or medians for continuous variables, and as percentages for cat-
egorical variables. Comparisons between normal and abnormal liver
enzyme groups for categorical variables were performed using
Fisher’s exact test. The analysis of variance or the Wilcoxon
rank-sum test was used to explore differences between normal and ab-
normal liver enzyme groups for continuous variables. Treatment differ-
ences in changes from baseline to Days 1, 3, 5, and 31 since the start of
study drug infusion were analysed using an analysis of covariance
model with treatment and baseline value as covariates.
Stepwise logistic regression analysis was performed to determine
the variables associated with abnormal baseline values for LFTs.
Maximum likelihood parameter estimates of odds ratios with 95%
Wald confidence intervals were calculated. The assessment of correl-
ation was evaluated using the Spearman correlation coefficient.
Survival analysis was performed for the baseline normal/abnormal
LFTs groups, which were defined by laboratory normal ranges. Cumu-
lative survival curves for the normal/abnormal groups were con-
structed using the Kaplan–Meier methodology, and survival curves
were compared using the log-rank test. As AST is also a marker of
myocardial necrosis, we have repeated the analysis, excluding patients
with acute coronary syndrome. Statistical analyses were performed
using the SAS software version 9.2 (SAS Institute, Inc., Cary, NC,
USA). A two-sided significant level of 5% was considered the level
of statistical significance.
Results
Assessment of liver function tests
All LFTs were available in 1134 patients at baseline. Table 1 shows
that .20% of measured LFTs were abnormal and most of LFTs
alterations were moderate elevations.
Following the initiation of inotropic support, AP decreased at
Day 1 and thereafter showed a small rebound (Figure 1). Alanine
transaminase and AST decreased progressively over the 31 days
after inotrope therapy (Figure 1). Liver function tests response by
treatment can be seen in Supplementary material online, Figure
S1; treatment-specific decrements in AP levels paralleled greater
changes in BNP levels in the levosimendan arm than in dobutamine
arm during the initial days of treatment.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Distribution of liver function tests elevations
at baseline
ALT (%) AST (%) AP (%)
Normal 847 (75) 759 (67) 894 (79)
1–2 times of UNL 168 (15) 206 (18) 205 (18)
≥2–5 times of UNL 66 (6) 102 (9) 32 (3)
≥5 times of UNL 53 (5) 67 (6) 3 (0.3)
UNL, upper normal limit defined as 135 U\L for AP, 47 U\L for ALT, 37 U\L for AS.
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Factors associated with abnormal liver
function tests at baseline
Tables 2 and 3 show that in this population of ADHF patients ele-
vations in AP were associated with marked clinical and biochemical
signs of systemic congestion and elevated right-sided filling pres-
sure, whereas elevations in transaminases were associated with
clinical signs of hypoperfusion.
Clinical signs coincident with abnormal AP levels included a
greater incidence of peripheral oedema and tricuspid regurgitation,
a two-fold increase in the incidence of ascites, a greater creatinine
concentration, and a 1.5-fold increase in BNP concentrations com-
pared with patients with normal AP, in uni- and multi-variate ana-
lysis (Table 3). The Spearman correlation coefficient between
plasma levels of AP and BNP ranged from 0.21 to 0.26 at baseline,
Day 1, Day 3, or Day 5 (all P, 0.001), and was greater than the
Spearman correlation coefficient between plasma levels of transa-
minases and BNP (e.g. 0.04 for ALT and 0.06 for AST, at Day 5;
both non-significant).
Tables 2 and 4 further show that abnormal ALT and/or AST
levels at baseline were associated with various clinical signs of
hypoperfusion: lower SBP, higher heart rate, and higher prevalence
of cold extremities. Abnormal ALT and/or AST were also asso-
ciated with a three-fold higher incidence of acute myocardial in-
farction, a lower incidence of a history of HF, and a lower
incidence of worsening HF. Abnormalities of transaminases were
further associated with a lower use of oral beta-blockers before
admission compared with normal transaminases.
Factors associated with high AP or high transaminases were
hardly affected by the occurrence of acute myocardial infraction
(See Supplementary material online, Table S1a and b).
No difference was also seen between factors associated with ab-
normal AST and those associated with abnormal ALT (data not
shown).
Abnormal liver function tests and
outcome
All-cause mortality rates of the SURVIVE population were 13% at
31 days and 27% at 180 days16. Table 2 shows that abnormal AP
was not associated with an overmortality at 31 days, but was at
180 days (23.5 vs. 33.8%, normal vs. abnormal AP, respectively,
P ¼ 0.001). Abnormal elevations in levels of at least one transamin-
ase was associated with an immediate and persistent overmortality,
with an almost two-fold greater 31-day mortality compared with
patients with normal transaminases (17.7 vs. 8.3%; P, 0.001)
and a greater 180-day mortality (31.8 vs. 22.1%, P, 0.001)
(Table 2).
Kaplan–Meier curves over 180 days were drawn based on
normal vs. abnormal values of baseline LFTs. Kaplan–Meier ana-
lysis found log-rank P-values ,0.001 for both abnormal AP and ab-
normal transaminases. Figure 2 illustrates the immediate negative
effect of abnormal transaminases and the lack of effect of abnormal
AP on the short-term outcome. Figure 2 also illustrates similar
long-term overmortality in abnormal AP or transaminases.
Of note, Figure 3 shows that results remained unchanged for AP
and ALT when patients with acute myocardial infarction were
excluded (n ¼ 941; log-rank P, 0.001 for AP and P ¼ 0.035 for
ALT); overmortality was also present although not statistically sig-
nificant for abnormal AST (log-rank P ¼ 0.07).
Data in Table 5 affirm a lack of additive values of abnormal trans-
aminases and abnormal AP on the long-term outcome. Abnormal
transaminases alone, abnormal AP alone, or combined transami-
nases and AP abnormalities were characterized by similar
180-day mortality (30.0, 31.0, and 36.9%, respectively), all of
which were greater than the mortality rate among patients with
normal LFTs (20.1%). Likewise, multi-variate analysis identified
AP as a factor independently associated with 180-day mortality
(Supplementary material online, Table S2).
Of note, though the absolute values of LFTs at baseline were
associated with outcome, changes of LFTs during the initial 5
days (decrease or increase) were not associated with the
outcome except a worse mortality (at both 30 and 180 days) in
patients that decreased AP (Table 6 and Supplementary material
online, Table S3); the decrease in AP during the initial 5 days is
even associated with a worse 31-day (Supplementary material
online, Table S3) and 180-day mortality than the increase in AP
(Table 6).
Discussion
This analysis of the SURVIVE database identified that (i) cardiohe-
patic dysfunction is present in about a half of this cohort of patients
with severe ADHF and (ii) LFTs can be used as surrogates of
haemodynamics. Biochemical signs of cholestasis were associated
with marked signs of systemic congestion and elevated right-sided
filling pressure, while biochemical signs of liver cytolysis were asso-
ciated with clinical signs of hypoperfusion. Cardiohepatic dysfunc-
tion was associated with increased long-term mortality.
Heart failure-induced cholestasis
In the present study, abnormal plasma AP (alone or in conjunction
with abnormal transaminase levels) was seen in 20% of ADHF
patients at baseline. High levels of AP at baseline were associated
with clinical and biochemical signs of marked systemic congestion
and elevated right-sided filling pressure, including peripheral
oedema, ascites, tricuspid regurgitation, and high plasma levels of
Figure 1 Time-course of liver enzymes in acute decompen-
sated heart failure patients from the time of inotrope administra-
tion to 31 days. Absolute values of liver enzymes over time
(*P ¼ 0.01 vs. baseline values).
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creatinine and BNP. Our results are in line with studies showing
that biochemical markers of cholestasis, including bilirubin,
g-glutamyl transpeptidase, or AP, are increased in the plasma of
patients with elevated central venous pressure13 or severe tricus-
pid regurgitation.7
The mechanism by which systemic congestion and elevated
right-sided filling pressure may alter biochemical markers of cho-
lestasis remains uncertain. In ADHF patients, the marked increase
in the vena cava and centrilobular pressure is transmitted back to
liver sinusoids (Figure 3).18 –20 It is highly likely that congestion in
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Table 2 Demographic characteristics, medical history, signs, and symptoms at admission, drugs before admission and
mortality depending on normal/abnormal values of liver function tests
Normal AP Abnormal AP P-value Normal ALT
and AST
Abnormal ALT
and/or AST
P-value
n 894 240 716 418
Age (years) 66.8 66.2 0.450 66.9 66.2 0.297
Weight (kg) 79.2 79.3 0.943 79.7 78.4 0.206
Height (cm) 169 170 0.020 169 169 0.445
Male (%) 70.8 75.8 0.145 71.7 72.2 0.838
Caucasian (%) 94.6 94.6 .0.999 93.7 96.2 0.101
Clinical signs at baseline
SBP (mmHg) 117 114 0.015 117 114 0.010
DBP (mmHg) 71 70 0.196 71 70 0.446
HR (b.p.m.) 83 83 0.955 81 87 ,0.001
Peripheral oedema (%) 65.4 78.8 ,0.001 71.2 63.2 0.005
Ascites (%) 17.3 31.7 ,0.001 22.2 17.1 0.047
Cold extremities (%) 20.7 25.8 0.094 19.6 25.6 0.021
Biochemical parameters at baseline (median)
ALT (IU/L) 26.0 31.5 ,0.001 21.0 59.0 ,0.001
AST (IU/L) 28.0 83.0 ,0.001 23.0 60.0 ,0.001
AP (IU/L) 83.0 173.5 0.001 90.0 101.0 ,0.001
Creatinine (mM/L) 120.0 143.2 ,0.001 123.4 127.4 0.289
BNP (pg/mL) 1027 1606 ,0.001 1070 1341 ,0.001
Cardiovascular history (%)
Previous CHF 88.7 89.2 0.909 92.9 81.8 ,0.001
Previous MI 68.9 67.9 0.814 68.2 69.6 0.642
Hypertension 64.1 59.2 0.175 62.9 63.4 0.899
Atrial fibrillation/flutter 46.5 53.3 0.069 50.1 44.3 0.057
Diabetes mellitus 33.1 40.0 0.047 34.1 35.4 0.651
Initial hospitalization characteristics (%)
Worsening HF 79.3 81.3 0.528 88.3 65.1 ,0.001
AMI 18.6 11.3 0.002 8.8 31.1 ,0.001
LVEF 24.0 23.3 0.054 24.1 23.5 0.070
Tricuspid regurgitation 46.0 53.3 0.049 51.7 40.4 ,0.001
Cardiovascular medications at admission (%)
ACE-I/ARB use 72.2 65.4 0.046 73.5 66.0 0.008
BB use 51.8 44.2 0.006 53.6 44.3 0.003
All-cause mortality (%)
At 31 days 11.1 14.2 0.213 8.3 17.7 ,0.001
At 180 days 23.5 33.8 0.002 22.1 31.8 ,0.001
n, 1134; ACE-I, angiotensin-converting enzyme inhibitor; ALT, alanine transaminase; AMI, acute myocardial infarction during current admission; AP, alkaline phosphatase; ARB,
angiotensin receptor blocker; AST, aspartate transaminase; BB, beta-blocker; BNP, B-type natriuretic peptide; CHF, chronic heart failure; DBP, diastolic blood pressure; HR, heart
rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NS, not significant; SBP, systolic blood pressure.
Abnormal LFTs are defined in Table 1.
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liver sinusoids would compress any collapsible structure within the
lobule, including bile canaliculi and ductules. Raised hydrostatic
pressure in liver sinusoids has been shown to increase the size
of liver cells;19 the latter might further compress bile canaliculi.
Those phenomena, named the ‘starling resistor’21 in various
organs such the lung and the brain, are suggested, in the present
study to also apply in the liver. Compression of bile ducts in the
way described might compromise bile flow and direct bile produc-
tion (including AP) towards the blood. The deterioration of cre-
atinine in our patients with elevated AP (and not in patients with
elevated transaminase) is in line with an increased venous conges-
tion.22,23 Hence, our study strongly suggests that AP is a biological
marker of liver congestion and of the extent of right-sided filling
pressure in ADHF patients.
Our data suggest that abnormal AP did not affect the short-term
outcome. This is consistent with various studies showing that the
extent of systemic congestion, including the increase in body
weight24 or elevated levels of central venous pressure,25 at admis-
sion for ADHF, did not affect in-hospital mortality but rather the
rate of rehospitalization. Our study found that decreased AP par-
alleled a decrease in BNP. This may be interpreted as an indication
that improvement in heart function and in liver congestion might
lead to reopening of the biliary tract and to reductions in AP
plasma levels. Extending that reasoning, our new data suggest
that plasma AP levels in ADHF patients mostly reflect bile duct
compression or decompression and not cell death. It is therefore
understandable that AP levels had no influence on short-term
survival.
Heart failure-induced liver cytolysis
In accordance with previous reports, our study shows that ele-
vated levels of transaminases resolve rapidly in response to inten-
sive medical therapy based on inotropes.15 Elevated plasma levels
of transaminases typically result from a leak of ALT and/or AST
from damaged hepatocytes into the bloodstream. In the present
study, AST and ALT showed a rapid normalization within the
first 5 days, with a more rapid plasma reduction for AST than
for ALT, as previously described.8 However, as shown in Table 6,
the decline in transaminases is not always indicative of liver recov-
ery and good outcome.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Multi-variate analysis of factors that predicted
abnormal alkaline phosphatase
OR Lower
CI
Upper
CI
P-value
Ascites (yes/no) 1.808 1.276 2.561 0.002
Peripheral oedema
(yes/no)
1.724 1.276 2.561 0.001
Diabetes mellitus
(yes/no)
1.460 1.067 1.998 0.018
BNP (pg/mL per 100) 1.026 1.014 1.032 ,0.0001
Creatinine (mM/L) 1.004 1.001 1.006 0.002
SBP (mmHg) 0.989 0.980 0.997 0.008
AP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase;
BNP, B-type natriuretic peptide; CI, confidence interval; MI, myocardial infarction;
OR, odds ratio; SBP, systolic blood pressure.
Of note, AST and ALT were excluded from this analysis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Multi-variate analysis of factors that predicted
abnormal alanine transaminase and/or abnormal
aspartate transaminase
OR Lower
CI
Upper
CI
P-value
Acute MI during current
admission (yes/no)
3.138 2.010 4.899 ,0.0001
BNP (pg/mL per 100) 1.020 1.011 1.028 ,0.0001
HR (b.p.m.) 1.018 1.010 1.026 ,0.0001
SBP (mmHg) 0.990 0.983 0.998 0.010
Beta-blocker at admission
(yes/no)
0.690 0.526 0.905 0.007
Worsening heart failure
during current
admission (yes/no)
0.395 0.263 0.595 ,0.0001
HR, heart rate; MI, myocardial infarction.
Of note, AP was excluded from this analysis.
Figure 2 Kaplan–Meier curves of mortality based on (A) abnormal or normal alkaline phosphate at baseline, or (B) abnormal or normal
transaminases. ALT, alanine transaminase; AST, aspartate transaminase.
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In our study, a profile of abnormal transaminase elevation was
associated with signs of hypoperfusion, including hypotension,
tachycardia, and cold extremities. This is consistent with previous
reports9,26 showing that hepatic cytolysis is related to hypoperfu-
sion and/or hypooxygenation of the liver cells of the centrilobular
region (‘nutmeg liver’) that are the more distant from the dual cir-
culatory supply of the hepatic artery and portal veins (Figure 4). We
think it likely therefore that elevated levels of transaminases
reflected liver ischaemia secondary to hypoperfusion caused by
rapid deterioration in cardiovascular function. This conjecture is
supported by the unfavourable short-term prognosis associated
with abnormal transaminases in the present study.
Liver function tests and long-term
prognosis
Acute decompensated heart failure patients requiring inotrope
treatment represent a critically ill group of patients with high
short- and long-term mortality rates. Many predictive factors
Figure 3 Log-rank analysis of 180-day mortality, acute myocardial infarction excluded or not. P, 0.001 for AP, P ¼ 0.035 for ALT, P ¼ 0.07
for AST.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Additive values of abnormal transaminases
and abnormal alkaline phosphatase on a short- and
long-term outcome
AST and ALT
normal
AST and/or ALT
abnormal
30-day mortality
AP (%)
Normal 46/587 (7.8) 53/307 (17.3)
Abnormal 13/129(10.0) 21/111 (18.9)
180-day mortality
AP (%)
Normal 118/587 (20.1) 92/307 (30.0)
Abnormal 40/129 (31.0) 41/111 (36.9)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6 Effect of change of liver function tests from
baseline to Day 5 on 180-day mortality
Alive Died
AP (n ¼ 883) (%)
Decrease 319 (73.8) 113 (26.2)
Increase 373 (82.7) 78 (17.3)
Log-rank P ¼ 0.001
ALT (n ¼ 883) (%)
Decrease 350 (76.3) 109 (23.8)
Increase 342 (80.7) 82 (19.3)
Log-rank P ¼ 0.111
AST (n ¼ 883) (%)
Decrease 362 (78.7) 98 (21.3)
Increase 330 (78.0) 93 (22.0)
Log-rank P ¼ 0.792
ALT, alanine transaminase; AP, alkaline phosphatase; AST, aspartate transaminase.
Subjects who have Day 5 ALT, AST, and AP assessment are included to the
analysis.
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have been described that aid risk stratification of patients and
decision-making for ‘invasive’ treatment options (cardiac resyn-
chronization therapy, left ventricular assist devices, transplantation,
etc.). The present study shows that impaired hepatic biochemistry
was associated with a 50% increase in the 180-day mortality rate
(30% absolute mortality in ADHF patients with altered LFTs
compared with 20% absolute mortality in patients with normal
LFTs) and should be tested as an additional risk factor of poor
outcome. High levels of AP and/or transaminases likely reflected
the severity of the underlying right-sided and/or left-sided HF.
Acute myocardial infarction—more prevalent in the group of
patients with elevated transaminases—may have interacted with
those results. In our examination of this matter, the prognostic
value of abnormal ALT—but not abnormal AST—persisted inde-
pendently of the acute myocardial infarction status.
Whether the severity of liver damage influences by itself the
prognosis, or only reflects the severity of the HF remains still
unclear.
Limitations
This is a retrospective analysis based on a cohort of patients that
did not represent the entire ADHF population.27 Patients with
severe liver injury were excluded from SURVIVE. Furthermore, in-
vasive haemodynamic data and liver imaging tests were not avail-
able. Concerning the panel of LFTs, unfortunately other markers
of liver function, such as bilirubin, albumin, or prothrombin time
were not measured. Cholestasis, though, is followed by the in-
crease in bilirubin or AP as well. Measuring prothrombin time
may also be confusing in patients receiving anticoagulants. This
trial may boost future prospective trials to compare the changes
in all LFTs along with haemodynamic and imaging techniques in
AHF patients.
Clinical implications
Measurements of LFTs should be recommended in the early phase
of ADHF management. Abnormal LFTs signify the presence of car-
diohepatic syndromes and, most importantly, indicate the mechan-
ism of liver injury and of its related heart dysfunction: liver
congestion related to ‘backward’ HF in case of elevated AP and/
or liver ischaemia related to ‘forward’ HF in case of elevated trans-
aminases. Abnormal LFTs may therefore offer a guide to the most
appropriate management of ADHF patients. Priority should there-
fore be directed towards reducing congestion in cases of increased
AP and/or towards improving perfusion in cases of increased trans-
aminases. Abnormal LFTs are also indicative of an unfavourable
long-term outcome and this knowledge may inform future treat-
ment strategies.
In summary, the present study describes cardiohepatic dysfunc-
tion in about half of patients presenting with ADHF that required
inotrope treatment. Cardiohepatic syndromes share some
common pathophysiological mechanisms with cardiorenal syn-
dromes, such as the increase in venous congestion and/or
reduced cardiac output leading to the worsening of renal function.3
Our study further shows that high levels of transaminases were
associated with a short-term overmortality that was not seen
with increased AP. Future studies should give attention to the
Figure 4 Suggested mechanism of acute decompensated heart failure-induced cholestasis and/or liver cell necrosis. Within each normal liver
lobule, blood easily flows from portal veins (or hepatic artery) through the sinusoids into the centrilobular vein, vena cava, and right atrium. In
the other hand, bile is secreted into a network of minute bile caniliculi situated between adjacent hepatocyte. Bile canaliculi originate close to
the centrilobular region and join to form bile ductules and ducts at the periphery of the lobule. In ADHF patients, congestive liver sinusoids
would likely compress bile canaliculi and ductules by increased hydrostatic pressure and increase in the size of liver cells; this phenomenon is
named ‘Starling resistor’. Hepatic cytolysis is related to hypoperfusion and/or hypooxygenation of the liver cells of the centrilobular region
(‘nutmeg liver’) that are the more distant from the dual circulatory supply of the hepatic artery and portal veins. AHF, acute heart failure;
AP, alkaline phosphatase; BNP, B-type natriuretic peptide.
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place of cardiohepatic syndromes, including the use of liver bio-
markers, in the diagnosis and the management of ADHF.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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